← All trials
NCT04704869
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2017
- Primary completion
- Dec 31, 2021
- Completion date
- Aug 31, 2022
- First posted
- Jan 12, 2021
- Last posted
- Oct 12, 2021
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas at HoustonLead sponsor
- Baylor UniversityCollaborator
- University of Texas at HoustonOverall official - principal investigator
- University of Texas at HoustonReponsible party - principal investigator
- University of LondonCollaborator
- NHS Blood and TransplantCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.